81 related articles for article (PubMed ID: 27599425)
21. Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.
Krishnadas DK; Wang Y; Sundaram K; Bai F; Lucas KG
Tumour Biol; 2017 Jul; 39(7):1010428317701309. PubMed ID: 28677424
[TBL] [Abstract][Full Text] [Related]
22. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs.
Gomi S; Nakao M; Niiya F; Imamura Y; Kawano K; Nishizaka S; Hayashi A; Sobao Y; Oizumi K; Itoh K
J Immunol; 1999 Nov; 163(9):4994-5004. PubMed ID: 10528204
[TBL] [Abstract][Full Text] [Related]
23. Induction of cytotoxic T-lymphocytes specific for malignant glioma by HLA dimer-based artificial antigen-presenting cells.
Xiaobing J; Xiaoling L; Ruen L; Fangcheng Z; Hongyang Z
Cancer Biother Radiopharm; 2007 Dec; 22(6):826-35. PubMed ID: 18158774
[TBL] [Abstract][Full Text] [Related]
24. In Vitro Generation of Antigen-Specific T Cells from Induced Pluripotent Stem Cells of Antigen-Specific T Cell Origin.
Kaneko S
Methods Mol Biol; 2016; 1393():67-73. PubMed ID: 27033216
[TBL] [Abstract][Full Text] [Related]
25. Selective elimination of undifferentiated human pluripotent stem cells using pluripotent state-specific immunogenic antigen Glypican-3.
Okada M; Tada Y; Seki T; Tohyama S; Fujita J; Suzuki T; Shimomura M; Ofuji K; Kishino Y; Nakajima K; Tanosaki S; Someya S; Kanazawa H; Senju S; Nakatsura T; Fukuda K
Biochem Biophys Res Commun; 2019 Apr; 511(3):711-717. PubMed ID: 30827508
[TBL] [Abstract][Full Text] [Related]
26. Cytotoxic T Lymphocytes Regenerated from iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor Model.
Kashima S; Maeda T; Masuda K; Nagano S; Inoue T; Takeda M; Kono Y; Kobayashi T; Saito S; Higuchi T; Ichise H; Kobayashi Y; Iwaisako K; Terada K; Agata Y; Numakura K; Saito M; Narita S; Yasukawa M; Ogawa O; Habuchi T; Kawamoto H
iScience; 2020 Apr; 23(4):100998. PubMed ID: 32259478
[TBL] [Abstract][Full Text] [Related]
27. Antitumor immune response of dendritic cells (DCs) expressing tumor-associated antigens derived from induced pluripotent stem cells: in comparison to bone marrow-derived DCs.
Iwamoto H; Ojima T; Hayata K; Katsuda M; Miyazawa M; Iida T; Nakamura M; Nakamori M; Iwahashi M; Yamaue H
Int J Cancer; 2014 Jan; 134(2):332-41. PubMed ID: 23824921
[TBL] [Abstract][Full Text] [Related]
28. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
Marzo AL; Lake RA; Robinson BW; Scott B
Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
[TBL] [Abstract][Full Text] [Related]
29. TCR-independent killing of B cell malignancies by anti-third-party CTLs: the critical role of MHC-CD8 engagement.
Lask A; Goichberg P; Cohen A; Goren-Arbel R; Milstein O; Aviner S; Feine I; Ophir E; Reich-Zeliger S; Hagin D; Klein T; Nagler A; Berrebi A; Reisner Y
J Immunol; 2011 Aug; 187(4):2006-14. PubMed ID: 21753148
[TBL] [Abstract][Full Text] [Related]
30. Ex vivo specific induction of CD8 positive anti-leukemia cytotoxic lymphocytes from umbilical cord blood.
Tan H; Liu X; Ye X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):129-33. PubMed ID: 17490538
[TBL] [Abstract][Full Text] [Related]
31. [Tumor-rejection antigens expressed on human squamous cell carcinoma].
Itoh K; Nakao M; Imai Y; Toh Y; Yamana H
Hum Cell; 1995 Dec; 8(4):149-54. PubMed ID: 8721083
[TBL] [Abstract][Full Text] [Related]
32. Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas.
Crowley NJ; Slingluff CL; Darrow TL; Seigler HF
Cancer Res; 1990 Feb; 50(3):492-8. PubMed ID: 2404572
[TBL] [Abstract][Full Text] [Related]
33. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer.
Stanislawski T; Voss RH; Lotz C; Sadovnikova E; Willemsen RA; Kuball J; Ruppert T; Bolhuis RL; Melief CJ; Huber C; Stauss HJ; Theobald M
Nat Immunol; 2001 Oct; 2(10):962-70. PubMed ID: 11577350
[TBL] [Abstract][Full Text] [Related]
34. CD11c+ blood dendritic cells induce antigen-specific cytotoxic T lymphocytes with similar efficiency compared to monocyte-derived dendritic cells despite higher levels of MHC class I expression.
Radford KJ; Turtle CJ; Kassianos AJ; Hart DN
J Immunother; 2006; 29(6):596-605. PubMed ID: 17063122
[TBL] [Abstract][Full Text] [Related]
35. Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.
Suzuki M; Curran KJ; Cheung NK
Pediatr Blood Cancer; 2015 Aug; 62(8):1326-36. PubMed ID: 25832831
[TBL] [Abstract][Full Text] [Related]
36. Tumor rejection antigens and tumor specific cytotoxic T lymphocytes.
Toes RE; Offringa R; Feltkamp MC; Visseren MJ; Schoenberger SP; Melief CJ; Kast WM
Behring Inst Mitt; 1994 Jul; (94):72-86. PubMed ID: 7998917
[TBL] [Abstract][Full Text] [Related]
37. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
38. Tracking in vivo migration and distribution of antigen-specific cytotoxic T lymphocytes by 5,6-carboxyfluorescein diacetate succinimidyl ester staining during cancer immunotherapy.
Xu WL; Li SL; Wen M; Wen JY; Han J; Zhang HZ; Gao F; Cai JH
Chin Med J (Engl); 2013 Aug; 126(16):3019-25. PubMed ID: 23981604
[TBL] [Abstract][Full Text] [Related]
39. [Tumor specific antigen and cytotoxic T lymphocytes].
Uenaka A; Nakayama E
Nihon Rinsho; 2005 Apr; 63 Suppl 4():568-73. PubMed ID: 15861712
[No Abstract] [Full Text] [Related]
40. Expansion of CD8+ cytotoxic T cells in vitro and in vivo using MHC class I tetramers.
Savage P; Millrain M; Dimakou S; Stebbing J; Dyson J
Tumour Biol; 2007; 28(2):70-6. PubMed ID: 17264539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]